LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Aeolus Pharmaceuticals, Inc. (OTCBB:AOLS) announced today the successful completion of the analysis of results from the Company’s phase 1 multiple-dose study of AEOL 10150 (“Study 102”). The clinical direction for AEOL 10150 is currently under consideration, with the most likely targets for an efficacy study as a protector of healthy cells in radiation therapy in lung cancer and/or head and neck cancer and Amyotrophic Lateral Sclerosis (“ALS” or “Lou Gehrig’s disease”).
